| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* School of Biological Sciences, University of Manchester, Manchester, M13 9PT, United Kingdom; Istituto per la Chimica di Molecole di Interesse Biologico, Consiglio Nazionale delle Ricerche, 80072, Arco Felice, Naples, Italy; and
Motac Neuroscience Ltd., Manchester MI3 9XX, U.K.
1Correspondence: J.B., 1.124 Stopford Building, School of Biological Sciences, University of Manchester, Oxford Rd, Manchester, M13 9PT, U.K. E-mail: j.brotchie{at}man.ac.uk and V.D.M., Istituto per la Chimica di Molecole di Interesse Biologico, Consiglio Nazionale delle Ricerche, Via Tolano 6, 80072 Arco Felice Naples, Italy. E-mail: vdimarzo{at}icmib.na.cnr.it
In recent years, cannabinoid receptors and their endogenous ligands (endocannabinoids) have been identified within the brain. The high density of CB1 cannabinoid receptors within the basal ganglia suggests a potential role for endocannabinoids in the control of voluntary movement and in basal ganglia-related movement disorders such as Parkinson’s disease. However, whether endocannabinoids play a role in regulating motor behavior in health and disease is unknown. Here we report the presence in two regions of the basal ganglia, the globus pallidus and substantia nigra, of the endocannabinoids 2-arachidonoylglycerol (2AG) and anandamide. The levels of the latter compound are ~threefold higher than those previously reported in any other brain region. In the reserpine-treated rat, an animal model of Parkinson’s disease, suppression of locomotion is accompanied by a sevenfold increase in the levels of the 2AG in the globus pallidus, but not in the other five brain regions analyzed. Stimulation of locomotion in the reserpine-treated rat by either of the two selective agonists of D2 and D1 dopamine receptors, quinpirole and R-(±)-3-allyl-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (Cl-APB), respectively, results in the reduction of both anandamide and 2AG levels in the globus pallidus. Finally, full restoration of locomotion in the reserpine-treated rat is obtained by coadministration of quinpirole and the selective antagonist of the cannabinoid CB1 receptor subtype, SR141716A. These findings indicate a link between endocannabinoid signaling in the globus pallidus and symptoms of Parkinson’s disease in the reserpine-treated rat, and suggest that modulation of the endocannabinoid signaling system might prove useful in treating this or other basal ganglia-related movement disorders.—Di Marzo, V., Hill, M. P., Bisogno, T., Crossman, A. R., Brotchie, J. M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease.
Key Words: anandamide • 2-arachidonoyl glycerol • cannabinoids • dopamine • receptors
This article has been cited by other articles:
|
|
 |
|
  T. Asua, A. Bilbao, M. A. Gorriti, J. A. Lopez-Moreno, M. del Mar Alvarez, M. Navarro, F. Rodriguez de Fonseca, A. Perez-Castillo, and A. Santos Implication of the Endocannabinoid System in the Locomotor Hyperactivity Associated with Congenital Hypothyroidism Endocrinology, May 1, 2008; 149(5): 2657 - 2666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Cao, L. Liang, J. R. Hadcock, P. A. Iredale, D. A. Griffith, F. S. Menniti, S. Factor, J. T. Greenamyre, and S. M. Papa Blockade of Cannabinoid Type 1 Receptors Augments the Antiparkinsonian Action of Levodopa without Affecting Dyskinesias in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Rhesus Monkeys J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 318 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Centonze, M. Bari, S. Rossi, C. Prosperetti, R. Furlan, F. Fezza, V. De Chiara, L. Battistini, G. Bernardi, S. Bernardini, et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis Brain, October 1, 2007; 130(10): 2543 - 2553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kofalvi, R. J. Rodrigues, C. Ledent, K. Mackie, E. S. Vizi, R. A. Cunha, and B. Sperlagh Involvement of Cannabinoid Receptors in the Regulation of Neurotransmitter Release in the Rodent Striatum: A Combined Immunochemical and Pharmacological Analysis J. Neurosci., March 16, 2005; 25(11): 2874 - 2884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Kim, D. Y. Lee, E. S. Chung, U. T. Oh, S. U. Kim, and B. K. Jin Transient Receptor Potential Vanilloid Subtype 1 Mediates Cell Death of Mesencephalic Dopaminergic Neurons In Vivo and In Vitro J. Neurosci., January 19, 2005; 25(3): 662 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. BASAVARAJAPPA and B. L. HUNGUND ROLE OF THE ENDOCANNABINOID SYSTEM IN THE DEVELOPMENT OF TOLERANCE TO ALCOHOL Alcohol Alcohol., January 1, 2005; 40(1): 15 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Soderstrom, Q. Tian, M. Valenti, and V. Di Marzo Endocannabinoids Link Feeding State and Auditory Perception-Related Gene Expression J. Neurosci., November 3, 2004; 24(44): 10013 - 10021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Carroll, P. G. Bain, L. Teare, X. Liu, C. Joint, C. Wroath, S. G. Parkin, P. Fox, D. Wright, J. Hobart, et al. Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study Neurology, October 12, 2004; 63(7): 1245 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Walter, T. Dinh, and N. Stella ATP Induces a Rapid and Pronounced Increase in 2-Arachidonoylglycerol Production by Astrocytes, a Response Limited by Monoacylglycerol Lipase J. Neurosci., September 15, 2004; 24(37): 8068 - 8074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Melis, M. Pistis, S. Perra, A. L. Muntoni, G. Pillolla, and G. L. Gessa Endocannabinoids Mediate Presynaptic Inhibition of Glutamatergic Transmission in Rat Ventral Tegmental Area Dopamine Neurons through Activation of CB1 Receptors J. Neurosci., January 7, 2004; 24(1): 53 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Bisogno, F. Howell, G. Williams, A. Minassi, M. G. Cascio, A. Ligresti, I. Matias, A. Schiano-Moriello, P. Paul, E.-J. Williams, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain J. Cell Biol., November 10, 2003; 163(3): 463 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Patel, D. J. Rademacher, and C. J. Hillard Differential Regulation of the Endocannabinoids Anandamide and 2-Arachidonylglycerol within the Limbic Forebrain by Dopamine Receptor Activity J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 880 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Marinelli, V. Di Marzo, N. Berretta, I. Matias, M. Maccarrone, G. Bernardi, and N. B. Mercuri Presynaptic Facilitation of Glutamatergic Synapses to Dopaminergic Neurons of the Rat Substantia Nigra by Endogenous Stimulation of Vanilloid Receptors J. Neurosci., April 15, 2003; 23(8): 3136 - 3144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gubellini, B. Picconi, M. Bari, N. Battista, P. Calabresi, D. Centonze, G. Bernardi, A. Finazzi-Agro, and M. Maccarrone Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission J. Neurosci., August 15, 2002; 22(16): 6900 - 6907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Maccarrone, T. Bisogno, H. Valensise, N. Lazzarin, F. Fezza, C. Manna, V. Di Marzo, and A. Finazzi-Agro Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer Mol. Hum. Reprod., February 1, 2002; 8(2): 188 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van der Stelt, W. B. Veldhuis, G. W. van Haaften, F. Fezza, T. Bisogno, P. R. Bar, G. A. Veldink, J. F. G. Vliegenthart, V. Di Marzo, and K. Nicolay Exogenous Anandamide Protects Rat Brain against Acute Neuronal Injury In Vivo J. Neurosci., November 15, 2001; 21(22): 8765 - 8771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van der Stelt, W. B. Veldhuis, P. R. Bar, G. A. Veldink, J. F. G. Vliegenthart, and K. Nicolay Neuroprotection by {Delta}9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo Excitotoxicity J. Neurosci., September 1, 2001; 21(17): 6475 - 6479. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
